| 2025-12-11 |
详情>>
内部人交易：
Casey Mark J共交易2笔
|
| 2025-11-06 |
详情>>
股本变动：
变动后总股本16249.90万股
|
| 2025-11-06 |
详情>>
业绩披露：
2025年三季报(累计)每股收益2.61美元,归母净利润4.23亿美元,同比去年增长497.09%
|
| 2025-11-06 |
财报披露：
美东时间 2025-11-06 盘前发布财报
|
| 2025-08-06 |
详情>>
业绩披露：
2025年中报每股收益3.87美元,归母净利润6.25亿美元,同比去年增长4115.18%
|
| 2025-05-08 |
详情>>
业绩披露：
2025年一季报每股收益3.22美元,归母净利润5.19亿美元,同比去年增长451.51%
|
| 2025-04-29 |
股东大会：
将于2025-06-20召开股东大会
会议内容 ▼▲
- 1.Election of three Class III directors to serve on the board of directors, each for a three-year term expiring at the 2028 Annual Meeting of Stockholders
2.Advisory vote to approve the compensation of our Named Executive Officers
3.Ratification of the appointment of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2025
4.Transaction of such other business as may properly come before the Annual Meeting or any adjournments or postponements thereof
|
| 2025-02-27 |
详情>>
业绩披露：
2024年年报每股收益-1.23美元,归母净利润-1.87亿美元,同比去年增长65.60%
|
| 2025-02-27 |
详情>>
业绩披露：
2022年年报每股收益-8.42美元,归母净利润-6.58亿美元,同比去年增长62.27%
|
| 2024-11-12 |
详情>>
业绩披露：
2024年三季报(累计)每股收益-0.71美元,归母净利润-1.06亿美元,同比去年增长70.96%
|
| 2024-08-08 |
详情>>
业绩披露：
2023年中报每股收益-2.69美元,归母净利润-2.36亿美元,同比去年增长23.18%
|
| 2024-08-08 |
详情>>
业绩披露：
2024年中报每股收益0.10美元,归母净利润1483.10万美元,同比去年增长106.29%
|
| 2024-05-10 |
详情>>
业绩披露：
2024年一季报每股收益-1.05美元,归母净利润-1.48亿美元,同比去年增长49.80%
|
| 2024-04-29 |
股东大会：
将于2024-06-13召开股东大会
会议内容 ▼▲
- 1.Election of three directors as Class II directors to serve on the board of directors, each for a three-year term expiring at the 2027 Annual Meeting of Stockholders
2.Advisory vote to approve the compensation of our Named Executive Officers
3.Amendment and restatement of the Novavax, Inc. Amended and Restated 2015 Stock Incentive Plan, as amended (the “2015 Stock Plan”) to increase the number of shares of Common Stock available for issuance thereunder by 6,500,000 shares
4.Amendment and restatement of the Novavax, Inc. 2013 Employee Stock Purchase Plan, as amended (the “ESPP”), to increase the number of shares of Common Stock available for issuance under the ESPP by 1,000,000 shares, such that the number of shares available for issuance is the lesser of (a) 2,155,000 shares of Common Stock increased on January 1 of each year by 5% of the share pool and (b) 3,510,264 shares of Common Stock
5.Ratification of the appointment of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2024
6.Transaction of such other business as may properly come before the Annual Meeting or any adjournments or postponements thereof
|
| 2024-02-28 |
详情>>
业绩披露：
2023年年报每股收益-5.41美元,归母净利润-5.45亿美元,同比去年增长17.16%
|
| 2023-11-09 |
详情>>
业绩披露：
2023年三季报(累计)每股收益-3.94美元,归母净利润-3.67亿美元,同比去年增长22.92%
|
| 2023-04-28 |
股东大会：
将于2023-06-15召开股东大会
会议内容 ▼▲
- 1.Election of three directors as Class I directors to serve on the board of directors, each for a three-year term expiring at the 2026 Annual Meeting of Stockholders
2.Advisory vote to approve the compensation of our Named Executive Officers
3.Advisory vote to approve the frequency of future Named Executive Officer compensation votes
4.Amendment to the Second Amended and Restated Certificate of Incorporation of Novavax, Inc., as amended (the “Certificate of Incorporation”) to reflect Delaware law provisions allowing officer exculpation
5.Amendment and restatement of the Novavax, Inc. Amended and Restated 2015 Stock Incentive Plan, as amended (the “2015 Stock Plan”) to increase the number of shares of the Company’s common stock, par value $0.01 (“Common Stock”), available for issuance thereunder by 6,170,000 shares
6.Ratification of the appointment of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2023
7.Transaction of such other business as may properly come before the Annual Meeting or any adjournments or postponements thereof
|
| 2022-08-09 |
复牌提示：
2022-08-08 16:00:20 停牌，复牌日期 2022-08-08 16:30:00
|
| 2022-05-02 |
股东大会：
将于2022-06-16召开股东大会
会议内容 ▼▲
- 1.Election of two directors as Class III directors to serve on the board of directors, each for a three-year term expiring at the 2025 Annual Meeting of Stockholders
2.Advisory vote to approve the compensation of our Named Executive Officers
3.Amendment and restatement of the Second Amended and Restated Certificate of Incorporation of Novavax, Inc., as amended (the “Certificate of Incorporation”) to eliminate the supermajority voting provisions
4.Amendment and restatement of the Amended and Restated By-laws of Novavax, Inc. (the “By-laws”) to eliminate the supermajority voting provisions
5.Amendment and restatement of the By-laws to permit stockholder access to the Company’s proxy statement with respect to the nomination of directors
6.Amendment and restatement of the Novavax, Inc. Amended and Restated 2015 Stock Incentive Plan, as amended (the “2015 Stock Plan”) to increase the number of shares of the Company’s common stock, par value $0.01 (“Common Stock”), available for issuance thereunder by 2,400,000 shares, and to limit the annual non-employee director compensation to $1.5 million and $1 million for the chairman of the Board and Board members, respectively
7.Amendment and restatement of the Novavax, Inc. 2013 Employee Stock Purchase Plan (the “ESPP”), as amended, to increase the number of shares of Common Stock available for issuance under the ESPP by 550,000 shares, such that the number of shares available for issuance is the lesser of (a) 1,100,000 shares of Common Stock increased each year by 5% and (b) 1,650,000 shares of Common Stock
8.Ratification of the appointment of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2022
9.Transaction of such other business as may properly come before the Annual Meeting or any adjournments or postponements thereof
|
| 2021-09-06 |
温馨提示：
美股因劳工节，9月6日休市一天
|
| 2021-05-03 |
股东大会：
将于2021-06-17召开股东大会
会议内容 ▼▲
- 1.Election of three directors as Class II directors to serve on the board of directors, each for a three-year term expiring at the 2024 Annual Meeting of Stockholders
2.Advisory vote to approve the compensation of our Named Executive Officers
3.Amendment and restatement of the Novavax, Inc. Amended and Restated 2015 Stock Incentive Plan, as amended (the “2015 Stock Plan”) to increase the number of shares of the Company’s common stock, par value $0.01 (our “Common Stock”), available for issuance thereunder by 1,500,000 shares
4.Ratification of certain April 2020 equity awards
5.Ratification of certain June 2020 equity awards
6.Ratification of the appointment of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2021
7.Transaction of such other business as may properly come before the Annual Meeting or any adjournments or postponements thereof
|
| 2020-05-13 |
股东大会：
将于2020-06-25召开股东大会
会议内容 ▼▲
- 1.To elect two directors as Class I directors to serve on the board of directors of the Company (the “Board”), each for a three-year term expiring at the 2023 Annual Meeting of Stockholders;
2.To consider and vote whether to approve, on an advisory basis, the compensation paid to our principal executive officer, principal financial officer, and two other most highly compensated individuals serving as executive officers on December 31, 2019 (collectively, the “Named Executive Officers”);
3.To amend and restate the Novavax, Inc. Amended and Restated 2015 Stock Incentive Plan, as amended (the “2015 Stock Plan”) to increase individual and non-employee director stock award limits granted to any person in any calendar year, and to increase the number of shares of the Company’s common stock, par value $0.01 (our “Common Stock”), available for issuance thereunder by 7,100,000 shares;
4.To ratify the appointment of Ernst & Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2020;
5.To transact such other business as may properly come before the Annual Meeting or any adjournments or postponements thereof.
|
| 2019-05-16 |
股东大会：
将于2019-06-28召开股东大会
会议内容 ▼▲
- 1.To elect three directors as Class III directors to serve on the board of directors of the Company (the “Board”), each for a three-year term expiring at the 2022 Annual Meeting of Stockholders;
2.To consider and vote whether to approve, on an advisory basis, the compensation paid to our principal executive officer, principal financial officer, and two other most highly compensated individuals serving as executive officers on December 31, 2018 (collectively, the “Named Executive Officers”);
3.To amend and restate the Novavax, Inc. Amended and Restated 2015 Stock Incentive Plan, as amended (the “2015 Stock Plan”) to increase the number of shares of the Company’s common stock, par value $0.01 (our “Common Stock”), available for issuance thereunder by 1,000,000 shares;1
4.To amend and restate the Novavax, Inc. Amended and Restated 2013 Employee Stock Purchase Plan, (the “ESPP”) to increase the number of shares of the Company’s Common Stock available for issuance thereunder by 200,000 shares;2
5.To ratify the appointment of Ernst & Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2019;
6.To transact such other business as may properly come before the Annual Meeting or any adjournments or postponements thereof.
|
| 2019-05-10 |
详情>>
拆分方案：
每20.0000合并分成1.0000股
|
| 2019-04-01 |
股东大会：
将于2019-05-08召开股东大会
会议内容 ▼▲
- 1.An amendment to the Company’s Second Amended and Restated Certificate of Incorporation to effect a reverse stock split of the Company’s issued and outstanding common stock at a ratio of 1-for-20;
2.Any other business properly brought before the Special Meeting.
|
| 2018-04-30 |
股东大会：
将于2018-06-14召开股东大会
会议内容 ▼▲
- 1.To elect two directors as Class II directors to serve on the board of directors of the Company (the “Board”), each for a three-year term expiring at the 2021 Annual Meeting of Stockholders;
2.To consider and vote whether to approve, on an advisory basis, the compensation paid to our principal executive officer, principal financial officer, and three other most highly compensated individuals serving as executive officers on December 31, 2017 (collectively, the “Named Executive Officers”);
3.To amend and restate the Novavax, Inc. Amended and Restated 2015 Stock Incentive Plan, as amended (the “2015 Stock Plan”) to increase the number of shares of the Company’s common stock, par value $0.01 (our “Common Stock”), available for issuance thereunder by 20,000,000 shares;
4.To amend and restate the Novavax, Inc. Amended and Restated 2013 Employee Stock Purchase Plan, (the “ESPP”) to increase the number of shares of the Company’s Common Stock available for issuance thereunder by 4,000,000 shares;
5.To ratify the appointment of Ernst & Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2018;
6.To transact such other business as may properly come before the Annual Meeting or any adjournments or postponements thereof.
|
| 2017-04-28 |
股东大会：
将于2017-06-15召开股东大会
会议内容 ▼▲
- 1.To elect two directors as Class I directors to serve on the board of directors of the Company (the “Board”), each for a three-year term expiring at the 2020 Annual Meeting of Stockholders;
2.To consider and vote whether to approve, on an advisory basis, the compensation paid to our principal executive officer, principal financial officer, and three other most highly compensated individuals serving as executive officers on December 31, 2016 (collectively, the “Named Executive Officers”);
3.To consider and vote, on an advisory basis, holding future executive compensation advisory votes every three years, every two years, or every year;
4.To amend and restate the Novavax, Inc. Amended and Restated 2015 Stock Incentive Plan (the “2015 Stock Plan”) to include a minimum vesting requirement applicable to all awards, define the plan administrator’s authority to accelerate the vesting of time- and performance-based awards on a change in control of the Company, expressly prohibit the payment of dividends and dividend equivalents on unvested awards, and increase the number of shares of the Company’s common stock, par value $0.01 (our “Common Stock”), available for issuance thereunder by 5,000,000 shares;
5.To ratify the appointment of Ernst & Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2017;
6.To transact such other business as may properly come before the Annual Meeting or any adjournments or postponements thereof.
|
| 2016-04-20 |
股东大会：
将于2016-06-09召开股东大会
会议内容 ▼▲
- 1.To elect three directors as Class III directors to serve on the board of directors of the Company (the “Board”), each for a three-year term expiring at the 2019 Annual Meeting of Stockholders;
2.To amend and restate the Novavax, Inc. 2015 Stock Incentive Plan (the “2015 Stock Plan”) and to increase the number of shares of the Company’s common stock, par value $0.01 (our “Common Stock”), available for issuance thereunder by 6,000,000 shares;
3.To amend and restate the Novavax, Inc. 2013 Employee Stock Purchase Plan (the “ESPP”) and to increase the number of shares of the Company’s Common Stock available for issuance thereunder by 1,000,000 shares;
4.To ratify the appointment of Ernst & Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2016;
5.To transact such other business as may properly come before the Annual Meeting or any adjournments or postponements thereof.
|